03:45:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaOB Match
IndustriLäkemedel & Handel
Nordic Nanovector är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo.


2021-11-18 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning NANOV 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning NANOV 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning NANOV 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NANOV 0.00 NOK
2018-05-30 Årsstämma 2018
2018-05-30 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning NANOV 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning NANOV 0.00 NOK
2016-05-19 Kvartalsrapport 2016-Q1
2016-05-19 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014
2021-03-26 16:41:54
Oslo, Norway, 26 March 2021

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 26 March 2021 decided to grant 1,070,000 Performance Share
Units ("PSUs") to employees in accordance with the authorisation granted at the
Annual General Meeting held on 10 June 2020 (the "AGM").

The terms and conditions of the PSUs, which are part of the Company's long-term
incentive plan for employees, are described on pages 27-30 in the Company's
annual report for 2019.

The PSUs are granted without consideration. The PSUs are non-transferable and
will vest three years after the date of grant subject to satisfaction of the
applicable vesting conditions. Each vested PSU will give the holder the right to
acquire one share in the Company at an exercise price corresponding to the par
value of the shares being NOK 0.20.

In accordance with the resolution at the AGM, the PSUs are secured by a
corresponding number of free-standing warrants. The sole purpose of the warrants
is to ensure delivery of shares in the Company upon exercise of the PSUs. The
warrants do not give the PSU holders (or the option holders) a right to
subscribe for any additional shares in the Company.

Of the 1,070,000 allocated PSUs, 455,000 PSUs have been granted to members of
the Company's executive management. Peter Braun has been granted 350,000 PSUs.
20,000 PSUs have been granted to new employees and 245,000 PSUs have been
granted to other current employees.

The following primary insiders were granted PSUs on 26 March 2021:

Peter Braun new CEO was granted 350,000 PSUs to be delivered when joining Nordic
Nanovector. Peter Braun will hold 350,000 PSUs and 0 shares

Lars Nieba, interim CEO was granted 90,000 PSUs. Lars Nieba now holds 200,000
PSUs and 15,713 shares

Malene Brondberg, CFO was granted 90,000 PSUs. Malene Brondberg now holds
155,000 PSUs and 21,196 shares

Jostein Dahle, CSO was granted 45,000 PSUs. Jostein Dahle now holds 110,000
PSUs, 150,000 options and 204,958 shares including shares to related party

Marco Renoldi, COO was granted 45,000 PSUs. Marco Renoldi now holds 115,000
PSUs, 464,137 options and 92,888 shares

Rosemarie Corrigan, CQO was granted 45,000 PSUs. Rosemarie Corrigan now holds
110,000 PSUs and 2,436 shares

Gabriele Elbl, VP Global Regulatory Affairs was granted 45,000 PSUs. Gabriele
Elbl now holds 95,000 PSUs and 0 shares

Christine Wilkinson Blanc, CMO was granted 95,000 PSUs. Christine Wilkinson
Blanc now holds 95,000 PSUs, and 0 shares.

Fredrik Haavind, Head of Legal & Compliance was granted 25,000 PSUs. Fredrik
Haavind now holds 50,000 PSUs, and 0 shares.

The PSUs allocated to the management of the Company is in accordance with the
Board of Director's declaration on salaries and other remuneration to the senior
executive management, as approved by the Company's AGM.

The total number of outstanding options and PSUs are now 1,344,467 and 1,744,500
respectively. Subject to all vesting conditions being fulfilled exercise of the
options and PSUs would create a 3,14% dilution of the outstanding shares on a
fully diluted basis.

Primary insider notifications pursuant to the Market Abuse Regulation article 19
are attached.

For further information, please contact:

Jan H. Egberts, Chairman

Cell: +31 6 1467 2518

Email: janegberts@aol.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to the Market Abuse
Regulation article 19 and 5-12 of the Securities Trading Act.